1903800-11-2

KIN1408 is a small molecule activator of the RIG-1-like receptor (RLR) pathway that has antiviral activity. It induces interferon regulatory factor 3 (IRF3) activation and translocation into the nucleus in a concentration-dependent manner in HEK293 cells without inducing cellular toxicity. KIN1408 induces expression of the innate immune genes MDA5, RIG-1, Mx1, IRF7, and IFIT1 in THP-1 cells stimulated with phorbol 12-myristate 12-acetate (PMA; ). It exhibits concentration-dependent broad-spectrum antiviral activity against dengue virus 2 as well as the influenza A, Ebola, Nipah, and Lassa viruses.

KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against HCV, influenza A, dengue virus 2, Ebola, Nipah, and Lassa viruses[1][2].

[1] Green RR, et al. Transcriptional analysis of antiviral small molecule therapeutics as agonists of the RLR pathway. Genom Data. 2016 Feb 1;7:290-2. DOI:10.1016/j.gdata.2016.01.020
[2] Sowmya Pattabhi, et al. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol. 2015 Dec 16;90(5):2372-87. DOI:10.1128/JVI.02202-15